The TF Chem lab owned by
DeVries discovered that Antarctic fish were able to survive sub-zero temperatures under the polar icecaps thanks to glycoproteins or an "anti-freeze" that protect their cells.
Sirona and its subsidiary TFChem have now successfully synthesized compounds derived from these naturally occurring glycoproteins and created an anti-aging technology intended to protect people's skin, not just from cold temperatures, but UV damage, oxidative stress and other catalysts of visible aging.
The discovery is so significant in the biotech sector that it did not take long for the
"Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted
Sirona's anti-aging project is also being championed by Jacques Cousteau's son and grandson, Jean-Michel and Fabien Cousteau, who will lend their global brand to support the commercialization of this new anti-aging cosmetic technology, especially because it does not require harvesting any fish.
It has also attracted unwanted attention by multi-national cosmetic giants like L'oreal which see the potential of synthetic protein's promising anti-aging properties to develop its own product.
"It's a demonstration of how valuable this technology is being perceived by the industry and how competitive an industry it is," said Belenkie.
Sirona, with a modest market cap of
Biotech market analysts believe that Sirona's science is incredibly promising for investors looking for serious growth because of its diverse programs.
In addition to the anti-aging program developed by TFChem, the scientists at Sirona's French lab are also world renowned in the stabilization of carbohydrate molecules.
With some products fairly close to marketability and others showing multiple uses in the pipeline, Sirona has signed an agreement with Bloom Burton,
"We believe Sirona has more therapeutic opportunities than can be exploited by Sirona alone. We are excited to develop these assets in partnership with Sirona and monetize them at the appropriate time," said Bloom Burton President,
Last January, Sirona entered into a global exclusive licensing agreement with
In the same month, Sirona completed an exclusive licensing agreement with Wanbang Biopharmaceuticals (Wanbang Biopharma) for its anti-diabetic SGLT2 inhibitor in
Wanbang Biopharma is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes in
Christopher HoptonCFO Sirona Biochem Corp.Phone: 1.604.282.6064 Email: email@example.com